Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival?

Abstract

Summary:Murine double minute 2 (MDM2) inhibitors represent an opportunity to target p53 in solid tumors with wild-type TP53 and particularly in some sarcomas characterized by a consistent amplification of the MDM2 gene. In this issue of Cancer Discovery, LoRusso and colleagues and Koyama and colleagues report the results of two early-phase studies investigating two different TP53–MDM2 antagonists in patients with soft-tissue sarcomas and other solid tumors.See related article by LoRusso et al., p. 1802 (5) .See related article by Koyama et al., p. 1814 (8) .